Showing results (141-150 of 227) with videos related to
Sort By:
Pageof 23
Nature Communications|November 2, 2025
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical modelsFilippo Birocchi, Antonio J Almazan, Aiyana Parker, et al.Nature Biotechnology|June 17, 2020
Publisher Correction: Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editingBenjamin P Kleinstiver, Alexander A Sousa, Russell T Walton, et al.Frontiers in Oncology|May 24, 2021
Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent GlioblastomaJoseph S Durgin, Fraser Henderson, MacLean P Nasrallah, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patientsKatia Schlienger, Christina S Chu, Edward Y Woo, et al.Blood Advances|January 7, 2020
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangementValentina Nardi, Nora Ku, Matthew J Frigault, et al.Nature Medicine|April 18, 2018
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomasChristopher W Mount, Robbie G Majzner, Shree Sundaresh, et al.Blood Cancer Discovery|January 11, 2022
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesStefanie R Bailey, Sonika Vatsa, Rebecca C Larson, et al.Blood|March 31, 2025
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentViktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, et al.Blood Advances|April 25, 2022
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myelomaMatthew J Frigault, Michael R Bishop, Jacalyn Rosenblatt, et al.Blood Advances|August 3, 2021
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapyPeter G Miller, Adam S Sperling, Elliott J Brea, et al.Pageof 23